Radiotherapy with high-energy charged particles has become an attractive therapeutic
option for patients with several tumour types because this approach better spares healthy …

A cancer diagnosis is one of the most feared events. Rarely diagnosed before the late
twentieth century, cancer now competes with cardiovascular disease as the leading cause of …

Purpose: The summary presented herein represents Part I of the three-part series dedicated
to Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, discussing risk assessment …

Charged particle therapy is generally regarded as cutting-edge technology in oncology.
Many proton therapy centres are active in the USA, Europe, and Asia, but only a few centres …

Charged particle therapy has been largely driven and influenced by nuclear physics. The
increase in energy deposition density along the ion path in the body allows reducing the …

Immune-checkpoint inhibitors targeting cytotoxic T-lymphocyte antigen 4 (CTLA-4),
programmed cell death protein 1 (PD-1), or programmed cell death 1 ligand 1 (PD-L1) have …

Background The comparative risks of a second cancer diagnosis are uncertain after primary
cancer treatment with 3‐dimensional conformal radiotherapy (3DCRT), intensity‐modulated …

The use of charged particle therapy to control tumours non-invasively offers advantages
over conventional radiotherapy. Protons and heavy ions deposit energy far more selectively …

Prostate cancer has surpassed lung cancer as the most common cancer in men in the
United States. The NCCN Guidelines for Prostate Cancer provide multidisciplinary …

BACKGROUND Economic analyses of new technologies, such as proton‐beam
radiotherapy (PBT), are a public health priority. To date, no systematic review of the cost …